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Forgotten Fibrocytes: A Neglected,
Supporting Cell Type of the Cochlea
With the Potential to be an Alternative
Therapeutic Target in Hearing Loss
David N. Furness*
School of Life Sciences, Keele University, Keele, United Kingdom
Cochlear fibrocytes are a homeostatic supporting cell type embedded in the vascularized
extracellular matrix of the spiral ligament, within the lateral wall. Here, they participate
in the connective tissue syncytium that enables potassium recirculation into the scala
media to take place and ensures development of the endolymphatic potential that helps
drive current into hair cells during acoustic stimulation. They have also been implicated
in inflammatory responses in the cochlea. Some fibrocytes interact closely with the
capillaries of the vasculature in a way which suggests potential involvement, together
with the stria vascularis, also in the blood-labyrinth barrier. Several lines of evidence
suggests that pathology of the fibrocytes, along with other degenerative changes in
this region, contribute to metabolic hearing loss (MHL) during aging that is becoming
recognized as distinct from, and potentially a precursor for, sensorineural hearing loss
(SNHL). This pathology may underlie a significant proportion of cases of presbycusis.
Some evidence points also to an association between fibrocyte degeneration and
Ménière’s disease (MD). Fibrocytes are mesenchymal; this characteristic, and their
location, make them amenable to potential cell therapy in the form of cell replacement
or genetic modification to arrest the process of degeneration that leads to MHL. This
review explores the properties and roles of this neglected cell type and suggests potential
therapeutic approaches, such as cell transplantation or genetic engineering of fibrocytes,
which could be used to prevent this form of presbycusis or provide a therapeutic
avenue for MD.
Keywords: cochlear fibrocyte, cochlear lateral wall, metabolic hearing loss, Ménière’s disease, cell
replacement therapy
INTRODUCTION
The major tissues of the cochlea are notable for their discrete functional roles and the diversity of
cell types that each possesses. At the same time, these tissues display a complex interdependence
in which their disruption, either singly or in different combinations, leads to hearing impairment.
There are three main tissues: the sensory epithelium (organ of Corti), located on the basilar
membrane, that detects and transduces sound energy into an electrical response; the neural
component, i.e., auditory nerve fibers and spiral ganglion, that conveys the responses of the organ
of Corti along the auditory pathway; and the lateral wall, a homeostatic tissue that maintains
electrochemical conditions within the cochlea favorable to the optimal function, and potentially
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survival of the sensory organ and the neural elements. In addition
to these, there are also other tissue components whose functions
are probably less directly involved in hearing, such as the
endolymphatic sac and various periosteal linings (see for example
Standring, 2015).
The diversity of functions and cell types present in these
tissues means that there is a range of ways that degeneration
affecting different targets contributes to hearing loss. The
purpose of this review is to raise the profile of one cell type
whose importance has been underestimated and contribution
often neglected: the fibrocytes of the spiral ligament. A simple
search of PubMed using the search terms ‘‘cochlear hair cell’’
and ‘‘cochlear fibrocyte’’ makes this neglect clear as the former
(at the time of writing) obtained 11,557 hits whilst the latter
obtained 262, a ratio of 44:1. On the basis of scientific endeavor,
then, this might imply that fibrocytes contribute very little to
cochlear function. On the basis of human pathological studies
(Schuknecht and Gacek, 1993), however, the reality is that in fact,
a significant proportion of hearing loss cases are likely to have
either directly or indirectly a major contribution from lateral
wall, and likely fibrocyte, dysfunction.
THE DIFFERENT TYPES OF HEARING
LOSS
Five-hundred million people worldwide have some form
of hearing loss. Hearing loss is often subdivided into
sensorineural (SNHL) and conductive (CHL; Sheffield and
Smith, 2018). Around 90% is generally attributed to inner ear
damage of some type, due primarily to aging, ototoxic drugs
(chemotherapy/aminoglycoside antibiotics) and loud noises
(e.g., soldiers, miners) and using the definition above, this would
thus be considered SNHL where the sensory hair cells in the
organ of Corti and/or spiral ganglion nerve (SGN) cells that form
the auditory nerve are affected. SNHL also includes the recently
described ‘‘hidden hearing loss’’ resulting from synaptopathy
at the level of auditory nerve input (Viana et al., 2015). The
problem with this definition, however, is that hearing loss can
also result from cellular degeneration in the cochlea in the other
tissues noted above, sometimes separately, sometimes together.
Thus, some definitions include metabolic hearing loss (MHL),
where lateral wall structures (spiral ligament and stria vascularis)
are affected as distinct from SNHL (Schuknecht and Gacek,
1993; Dubno et al., 2013). Currently, no cure exists either for
MHL or SNHL, though hearing loss, in general, is managed by
prosthetics (hearing aids and cochlear implants).
The relative proportion of MHL and SNHL in age-related
hearing loss patients, and with what frequency both may be
present at some point in the patient’s disease progression, is
uncertain. Because SNHL is often quoted as the major cause of
hearing loss, hair cell repair or regeneration is the commonest
target of most research in cochlear therapies. However, the
pathological studies of human temporal bones by Schuknecht
and Gacek (1993) suggest that the greater proportion of such
acquired hearing loss could be MHL on the basis of a pattern
of lateral wall atrophy. Whilst this is likely to be contentious, if
correct, this would change our general perception of hearing loss.
As it stands, however, there is insufficient evidence to be certain,
so this needs to be confirmed.
The lack of data on the relative proportion of MHL compared
with SNHL is presumably because there are no good diagnostic
techniques to distinguish clearly between these disorders. Such
techniques are being developed on the basis of animal models
(Dubno et al., 2013; Vaden et al., 2017, 2018) and are likely to
be in place in the relatively near future. More refined diagnostic
techniques would enable the clinician to determine, with greater
accuracy than presently possible, the form of the hearing loss
and therefore identify patients who would be amenable to
appropriately targeted treatment.
THE STRUCTURE AND FLUID
COMPOSITION OF THE COCHLEAR DUCT
To understand the concept of lateral wall-based MHL, it is
necessary to review briefly the structure of the cochlea and
cochlear homeostasis, with an emphasis on the region of the
spiral ligament. The spiral cochlea contains the sensory organ of
Corti located in the cochlear duct which is the middle chamber
of three fluid-filled chambers (Figure 1) that run longitudinally
along the cochlea. These are the scala vestibuli and scala tympani,
which are in continuity at the cochlear apex and are filled with
perilymph, a solution high in sodium ions and containing a
number of other ions and substances, and the scala media that
contains endolymph which is high in potassium ions. The scala
media is separated from the other two compartments by a lining
of epithelial cells of various types, all of which are connected
by tight junctions that prevent paracellular translocation of ions
and other substances, thus forming a complete electrochemical
barrier between the inside of the scala media and the surrounding
tissues and extracellular spaces.
The tight junction barrier on the inside of the scala media
lining ensures that the composition of cochlear fluids is under
the control of the cells lining the epithelium, in the sense that
the only access between the inside of the duct and the outside
is through the plasma membranes of the cells facing the inside.
Hence the transfer of ions or substances of any kind is limited
to apical membrane channels or transporters on these cells.
Maintenance of the correct fluid composition in the different
compartments is thus dependent on each cell type contributing
to the re-distribution of ions in an appropriate manner. This
is vital for normal auditory function, specifically in providing
support for the function of the sensory hair cells (see review by
Wangemann, 2006).
The tight junctions in the organ of Corti occur between
the adjoining apical surfaces of hair cells and supporting cells,
which form a region called the reticular lamina. Each hair
cell is characterized by a sensory hair bundle that projects
into the endolymph in the scala media, whilst the cell bodies
below the reticular lamina are bathed in perilymph. During
the sensory functioning of the hair cells, the only route
for transfer of ions across this surface is through channels
located in the hair bundles; stimulation by sound causes
these mechanotransducer channels to open resulting in entry
predominantly of K+, but also Ca2+, which depolarizes the
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FIGURE 1 | Diagrammatic representation of the cochlea in section (inset) showing the chambers of the spiral and the location of scala media (sm) scala vestibuli (sv)
and scala tympani (st). The main panel shows a cross-section of the sm and the arrows indicate the two probable routes of recycling potassium through the organ of
Corti, perilymph and lateral wall, including the fibrocytes.
hair cells, resulting in the release of the neurotransmitter
glutamate at synapses between auditory nerve fibers and the
basal pole of the hair cells. This, in turn, leads to stimulation of
spiral ganglion neurons (SGNs) which then signal the hair-cell
response to the brain. Potassium ions exit the hair cells into
perilymph via basolateral potassium channels (see review by
Wangemann, 2006). To our knowledge, the supporting cell
apical surfaces do not express ion channels or transporters,
but the cells are connected sub-apically by gap junctions
which help to form an epithelial gap junction network as
described below.
In essence, continued active redistribution of the K+
ions results in a powerful battery, the endocochlear (or
endolymphatic) potential (EP) that drives current into the hair
cells whilst their transduction channels are open. Exhaustion of
K+ ions would reduce the magnitude of transduction; thus loss
of EP results in loss of auditory nerve function (Lang et al.,
2010). In addition, excessive K+ in hair cells appears to result
in hair-cell death (Nouvian et al., 2003). This toxicity can be
avoided only because potassium is continuously pumped out
of the perilymph. Failure to maintain the correct balance of
fluids within these compartments might also lead to volumetric
changes that result in endolymphatic hydrops, a likely origin
of Ménière’s disease (MD). The lateral wall tissue is of prime
importance in this process by contributing to two major routes
for recycling the K+ ions released into perilymph from the hair
cells (Figure 1). These routes involve transcellular relocation of
the K+ ions through the ligament. The source of the ions is
either directly from perilymph or via the gap-junction connected
supporting cells of the organ of Corti. The breakdown of these
homeostatic mechanisms can result in failure to recycle this
crucial ion between the different fluid-filled compartments of
the cochlea.
LATERAL WALL STRUCTURE AND
FUNCTION
The two major components of the lateral wall: the stria vascularis
and the spiral ligament, function together to maintain the EP
during K+ recycling. As shown in Figure 1, the recycling occurs
via the two main routes from the perilymph around the hair cell
bases. The first of these is a transcellular route (the epithelial
gap-junction network) via the cells of the outer sulcus which
are connected to each other by gap junctions composed of
connexins such as Cx26, Cx30 and Cx31 (Xia et al., 1998; Forge
et al., 1999; Mei et al., 2017). This is the epithelial gap junction
network and the cells involved form an epithelial syncytium
where their cytoplasmic compartments are in direct contact. Its
importance is exemplified by the fact that genetic mutations in
these genes are significant contributors to genetic hearing loss,
for example, GJB2 (Cx26), GJB6 (Cx30) and GJB3 (Cx31; see for
example Forge et al., 2003). Gap junctional proteins have also
been confirmed directly in histological studies to occur in the
human spiral ligament (Liu et al., 2017).
The second route for potassium transfer is through
perilymph. This also ends up at the lateral wall where potassium
ions enter the lateral wall gap-junction system (the connective
tissue gap junction network or syncitium).
The stria vascularis is a heavily vascularized three-cell layered
tissue composed of marginal cells facing the scala media,
intermediate cells and basal cells. This tissue lines the inner
curved surface of the spiral ligament between a spiral ridge
of tissue (the spiral prominence) and the junction of the
ligament with the upper boundary of the cochlear duct, Reissner’s
membrane. The ligament itself is longer, extending above and
below the stria vascularis; at its lower end is the anchor point
of the basilar membrane, whilst extending above Reissner’s
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membrane it lines the bony external wall to the upper boundary
of the spiral chamber (Figure 2). The ligament varies in width in
different cochlear turns, becoming wider towards the basal end of
the cochlea. Cell types and densities thus vary along the cochlear
duct, but quantitative information about these changes is, thus
far, limited.
The cell types of the ligament include perivascular endothelial
cells around capillaries, root cells (a large, branched cell type
projecting from near the basilar membrane anchorage and
midway into the ligament) and fibrocytes. There are five
main types of fibrocyte in mice, with differential morphology,
protein expression and location (Figure 2; Furness et al., 2009;
Mahendrasingam et al., 2011a,b) although in other studies, for
example in gerbil, these have been divided into several further
subtypes (Spicer and Schulte, 1996).
From electron microscopic studies, the fibrocytes are
distinguished by fine structural characteristics such as the density
of cytoplasm, content of cell organelles and the extent to which
the plasma membrane is folded (Figure 2). Thus, the least
complex of the cells structurally is the type I fibrocyte which has
an elongated shape, relatively light cytoplasm and few organelles,
and a minimal number of plasma membrane folds. Type II
and type V are structurally very similar to each other, have
relatively dense cytoplasm and multiple membrane folds. Type
III tend to have elaborately branched surfaces, and very dense
cytoplasm, with narrow cell bodies. Type IV cells are similar to
but generally larger than type III with intermediate amounts of
surface elaborations between type III and type II or type V.
The role of these various fibrocyte types is uncertain, but
they show other differences in characteristics in terms of protein
expression (Table 1). As with the epithelial syncitium, the gap
junction network of the ligament comprises several connexins
(Cx26, Cx30, Cx31 and Cx43). It is known that type I fibrocytes
are connected by gap junctions to the basal cells of the stria
vascularis (Forge et al., 2003), and that type II and type V
cells possess high levels of the Na, K, ATPase transporter,
whilst type I cells have less and type III and type IV cells
have little (Mahendrasingam et al., 2011a). To some extent,
these distributions have been confirmed in human tissues as
well (Liu et al., 2017), although type I cells were not found to
express the NaKATPase. This perhaps reflects age or sampling
issues of human tissues. Type II cells appear to be connected
to type I cells in the gap junction network. Other proteins
expressed in fibrocytes include the potassium channel Kir5.1
(Hibino et al., 2004), BK channels (Liang et al., 2003; Shen
et al., 2004), L-type Ca2+ channel (Liang et al., 2004) and
Na-K-Cl co-transporter 1 (NKCC1; Crouch et al., 1997) which
are likely to be involved in the recycling of K+. Type III
cells (alternatively called tension fibroblasts) contain prominent
cables of actin filaments and may modulate tension between the
basilar membrane and the bony wall of the cochlea (Henson
and Henson, 1988), but they also, uniquely amongst fibrocytes
of the cochlea, express aquaporin 1, implicating them in water
homeostasis (Mahendrasingam et al., 2011a).
Root cells have extensive broad processes penetrating into
the lower part of the ligament. They also have gap junctions
communicating with the surrounding cells and are supported by
a tubulin/microtubular cytoskeleton, presumably to maintain the
extensive branches (Jagger et al., 2010).
The homeostatic K+ recycling mechanism involving
fibrocytes is generally presumed necessary to ensure maximum
sensitivity of the sensory hair cells (Wangemann, 2006) and
also to maintain the conditions which ensure the continued
survival of other cochlear tissues. The K+ then travels to the stria
vascularis basal cells lying adjacent to the spiral ligament. Stria
vascularis function is perhaps better understood than that of the
ligament. The molecular players involved in the redistribution of
ions suggest a kidney like function, with concentration gradients
that drive the relocation of potassium. This is thought to be
initiated by transport into the basal cells via the gap junction
connections with type I fibrocytes (Figure 3). The stria vascularis
is also compartmentalized from the ligament by tight junctions
composed of claudin 11 in both humans and rodents (Kitajiri
et al., 2004; Liu et al., 2017), ensuring that cellular ion transport
mechanisms are the route for K+.
PHYSIOLOGICAL PROPERTIES OF
FIBROCYTES
Electrophysiological studies of fibrocytes have been fairly limited,
but there is evidence that they have unusual properties that
may be associated with a potassium recycling role. Typically
eukaryotic cells have a negative resting membrane potential,
but fibrocytes have been reported to possess positive potentials
in vivo of up to +12 mV (Yoshida et al., 2016). It has
been suggested that this contributes to the establishment of
appropriate ionic gradients inside the lateral wall that enable the
development of the EP through the stria vascularis. Studies of
the potentials within the ligament suggest it is slightly positive
compared with perilymph. Blockers of Na, K, ATPase decrease
K+ concentration within the fibrocytic zone and reduce EP
(Adachi et al., 2013) providing evidence for the role of fibrocytes
in maintaining EP.
Our study of glutamate transport properties of fibrocytes
in slices from rat pups (Furness et al., 2009) established that
the cells had a glutamate transporter-associated current that
corresponded with the amount of GLAST in them—i.e., type
II fibrocytes which express GLAST more than other fibrocytes
had greater glutamate transport capability than type I fibrocytes
which express less GLAST. Since GLAST is a co-transporter of
Na+ and K+, it may also contribute to the recirculation of K+.
However, during glutamate uptake, K+ is transported out of the
cytoplasm—thus GLAST would in principle be operating in an
opposing direction to the Na, K, ATPase with respect to K+.
Other physiological properties that have been directly
measured have been noted in in vitro studies of fibrocyte cultures.
These suggest that fibrocytes also possess chloride channels
(Qu et al., 2006).
A ROLE FOR FIBROCYTES IN
INFLAMMATORY RESPONSES
Cochlear inflammation is often triggered by middle ear infection
or damage caused by environmental insults such as acoustic
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FIGURE 2 | Lateral wall structure in a CD/1 mouse. The left panel shows a light microscopy section of stria vascularis (sv) spiral prominence (sp) and the spiral
ligament containing five types of fibrocyte (I—V). Scale bar = 50 µm. Panels (A–E) show fibrocyte types I to V by transmission electron microscopy. They have
varying numbers of small processes (arrows) and differences in the density of cytoplasm (cy) and organelle content. Scale bars: (A,C) = 5 µm; (B,D,E) = 2 µm
(adapted with permission from Mahendrasingam et al., 2011a).
TABLE 1 | Characteristic proteins of fibrocytes.
Protein Function Strongly expressing References
Caldesmon Calcium modulation Type III Mahendrasingam et al. (2011a)
S-100 Calcium modulation Type I, II and V Suko et al. (2000) and Mahendrasingam et al. (2011a)
Na, K-ATPase Sodium/potassium transport Type II and V Suko et al. (2000) and Mahendrasingam et al. (2011a)
Ca, ATPase Calcium transport Type I Ichimiya et al. (1994)
Na, K, Cl-cotransporter Sodium/potassium/chloride transport Type II, IV and V Qu et al. (2006)
NCBE Bicarbonate transporter Huebner et al. (2019)
GLAST Glutamate transport Jin et al. (2003) and Furness et al. (2009)
Kir5.1 Potassium channel Type II, IV, and V Hibino et al. (2004)
Ether-a-gogo Potassium channel Nie et al. (2005)
Kv3.1 Potassium channel So et al. (2001)
BK channels Potassium channel Liang et al. (2003)
ClC Chloride channels Qu et al. (2006)
Connexin 26, 30, 31, 43 Gap junction channel Forge et al. (2003)
AQP1 Water channel Type III Miyabe et al. (2002) and Mahendrasingam et al. (2011a)
Carbonic anhydrase Carbon dioxide-water converter Type I, III, IV and V Spicer and Schulte (1991)
Creatine kinase ADP-ATP cycling Type I, III, IV and V. Spicer and Schulte (1991)
Connective tissue growth factor (CTGF) Collagen metabolism Type IV Adams (2009)
Table illustrating some of the proteins known to be of functional relevance in fibrocytes and often used to characterize the different types.
trauma or ototoxic drugs. Fibrocytes are thought to play a
role in inflammatory responses in the cochlea and to offer a
potential for protection from inflammation that could lead on
to SNHL. In experimental models of inflammatory triggers,
immunostaining for Na, K, ATPase and Cx26 have been shown
to be decreased in labyrinthitis while in otitis media Cx26 is
reduced (Ichimiya et al., 2000). The same authors showed that
cultured spiral ligament fibrocytes release chemokines after
stimulation by proinflammatory cytokines, TNF-α or IL-1β.
IL-10 mediated protection from ototoxic drugs has also been
observed (So et al., 2001), suggested to be associated with an
anti-inflammatory response in fibrocytes (Woo et al., 2015).
Hence it is likely that as part of their homeostatic role, the
fibrocytes have anti-inflammatory capabilities that have the
potential to protect the cochlea from inflammation leading
to deafness.
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FIGURE 3 | Diagram showing potassium and other ion circulation and the formation of the EP within the lateral wall. In the stria vascularis and the spiral ligament,
K+ concentration gradients ([K+]) and potentials vary at different points in the tissue as shown. Gap junctions connect the spiral ligament fibrocytes together and also
connect them to basal cells and then intermediate cells of the stria vascularis. K+ entering from outer sulcus cells of the organ of Corti or directly from perilymph via
Na, K, ATPase or NKCC1 then flows through the syncytium of the ligament into the stria vascularis where it is transported to marginal cells and secreted into
endolymph. For protein identity, see key below diagram. Modified figure based on Hibino and Kurachi (2006) with additional data from Adachi et al. (2013).
LATERAL WALL AND THE
BLOOD-LABYRINTH BARRIER
As well as K+ recycling, the lateral wall is a major contributor
to the blood supply of the cochlea. In this context, the
functional relationship of lateral wall fibrocytes to the blood-
labyrinth barrier is of potentially great interest, but as yet
is unclear. It is likely that the stria vascularis is the main
site of the blood-labyrinth barrier, as indicated by its heavy
vascularization. It is perhaps less well known that the spiral
ligament is well vascularized (Carraro et al., 2016). Indeed,
ultrastructural studies suggest a close association between
some fibrocyte types and the blood vessels of the ligament
(Spicer and Schulte, 1996) including endfeet-like processes (Dai
and Shi, 2011), where material transport between blood and
labyrinth tissue is likely to be tightly controlled. Furthermore,
tracer studies showed that spiral ligament vessels have lower
permeability than those of stria vascularis, with tight junctional
barriers between the endothelial cells of the blood vessels
(Sakagami et al., 1982). How this influences the homeostatic
activities and barrier properties of the lateral wall remains to
be established.
More indirectly, a role for fibrocytes in vascular control of
the cochlear blood supply has been suggested. The study by Dai
and Shi (2011) found elevation of Ca2+ in fibrocytes generates
a Ca2+ signal to nearby vascular cells causing vasodilation of
capillaries. This coupling was also found to mediate sound-
stimulated cochlear blood flow increases.
LATERAL WALL PATHOLOGY IN HEARING
LOSS
Evidence from both animal and human deafness studies suggests
that degeneration of the lateral wall fibrocytes is associated with
hearing loss and a contributor probably to MHL. Time course
studies suggest that fibrocyte degeneration can precede hair cell
loss (Hequembourg and Liberman, 2001; Mahendrasingam et al.,
2011b), so it is possible to surmise that it could also lead to
SNHL by giving rise to a change in the composition of cochlear
fluids that negatively affect hair cells and neural elements. One
human deafness gene (DFN3) has been identified that has
degeneration of fibrocytes as its major pathology, accompanied
by severe reduction of the EP in an animal model (Minowa et al.,
1999), and fibrocyte degeneration has been reported in mice
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showing age-related hearing loss (Hequembourg and Liberman,
2001). We found early fibrocyte pathology, including damaged
and degenerating cells, in CD/1 mice that show accelerated
age-related hearing loss (Mahendrasingam et al., 2011b). The
degeneration was primarily, in its initial stages, in the form of
mitochondrial damage, as is found in other types of age-related
degeneration (see review by Zhu et al., 2019). These findings
led us to hypothesize that fibrocyte degeneration is a significant
cause of MHL leading to SNHL.
In their study of human temporal bones of a range of ages,
Kusunoki et al. (2004) found significant early loss of types II and
IV fibrocytes followed by types I and III, respectively. From the
ultrastructural studies noted above Spicer and Schulte (1996),
loss of type II cells and their association with blood vessels
might well compromise the blood-labyrinth barrier in the type
II location. This could lead to disturbances of cochlear fluid
composition, increased vulnerability to toxins, and deleterious
changes leading to further pathological alterations, potentially
loss of EP and hearing loss.
It should be noted, however, that it is not always clear that
loss of EP produces hearing loss. Although measurements of
EP in some cases of threshold elevation show EP losses (Mei
et al., 2017) others do not (Lukashkina et al., 2017). This lack
of consistency in data from the literature makes it harder to
make the case for MHL through stria or ligament dysfunction.
Nevertheless, the temporal bone studies showing that lateral wall
pathology is seen with deafness in older people remains a good
indicator that there is a link.
LATERAL WALL AND MÉNIÈRE’s DISEASE
As well as hearing loss, lateral wall pathology has been implicated
in MD. Whilst some of the symptoms of MD can be attributed
to a loss of the sensory hair cells in the inner ear, other
pathological changes have also been noted in endolymphatic
hydrops, a feature of MD. In a study of experimental (surgically
induced) endolymphatic hydrops in guinea pig, Nadol et al.
(1995) evaluated pathological changes throughout the cochlea
over a period of time up to 6 months. They found that
type I fibrocytes showed early changes with downregulation of
expression of a variety of proteins tested (e.g., S-100, Ca, ATPases
and other enzymes) and later type I and type II fibrocytes
showed reduction in Na, K, ATPases and connexin 26, along
with structural degeneration. This led Merchant et al. (2005) to
evaluate the relationship between endolymphatic hydrops and
MD in a human temporal bone archive. They found hydrops in
all MD cases, although not always MD in hydrops cases, and
concluded that spiral ligament pathology was clearly involved
with both hydrops and MD.
An evaluation of the CD/1 mice in our studies
(Mahendrasingam et al., 2011b) also hinted at a link between
MD and fibrocyte pathology. Although we did not report the
pathology at the time, it is evident that sections of the cochlea
show a distended cochlear duct, with Reissner’s membrane being
deformed (Figure 4) to an increasing extent with age, a possible
indicator of MD. Although this distortion was not always present
FIGURE 4 | Sections from a 3 week and 7 week CD/1 mouse cochlea
showing accelerated age-related hearing loss. Fibrocyte degeneration in
these mice has been reported (Mahendrasingam et al., 2011b) and can be
seen as loss of cell nuclei/thinning of the tissue (∗). The evidence for
progressive hydrops is indicated by the arrows, where Reissner’s membrane
is distorted at 3 weeks, but this distortion becomes more exaggerated at
7 weeks, implying an increase in volume. Scale bar = 50 µm (adapted with
permission from Mahendrasingam et al., 2011b).
in older CD/1 mice, it might suggest that fibrocyte degeneration
contributes to fluid changes in the cochlea.
Aquaporin 4 and 6 (proteins involved in water homeostasis)
expression also seem to be affected in MD (Ishiyama et al.,
2015) although aquaporin 1 (expressed by type III fibrocytes)
was not reported to be affected. Nevertheless, degeneration of
type III fibrocytes seems likely to occur along with the other
fibrocytes, as we have seen in our studies of CD/1 mouse lateral
wall degeneration, and this would cause loss of aquaporin 1 and
potentially osmotic changes. The role of aquaporin 1, therefore,
needs further investigation. The distribution of the glutamate
transporter GLAST, presumed to be involved in glutamate
recycling, is altered in the lateral wall in Ménière’s patients
(Ahmed et al., 2013). Build-up of glutamate in perilymph could
potentially lead to excitotoxicity in the cochlea, affecting the
SGNs nerve terminals with the hair cells; indeed glutamate
based excitotoxicty of SGN terminals on hair cells has been
demonstrated in a number of studies (see review by Pujol and
Puel, 1999). Finally, Ishiyama et al. (2007) found a significant
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reduction against age-matched controls in both stria and spiral
ligament volume in five temporal bones from humans suffering
fromMD.
Thus, although a direct, causal link between any specific
pathology and MD has yet to be established, there is good
evidence that fibrocyte degeneration is highly likely to be a
contributory factor.
FIBROCYTES AS A POTENTIAL TARGET
FOR THERAPY IN HEARING LOSS AND MD
The lateral wall of the cochlea is relatively superficial as a
structure, compared with hair cells or SGN. Substances could
potentially be introduced into this area through the round
window or an opening in the cochlear bony wall. Its superficial
location also means it is more accessible than deeper structures
for surgical intervention. The tough ligament itself is likely
to be better able to withstand surgical procedures or physical
manipulation than other more delicate tissues in the cochlea,
although with the proviso that disruption of the blood-labyrinth
barrier in the ligament, or of the tight junction network on the
inner surface of the scala media, might prove damaging. It has
proved possible to make a small opening in the bony wall of the
guinea pig cochlea through which electrodes can be introduced
into the ligament and stria vascularis (Yoshida et al., 2016). The
question then is what might be introduced into the ligament
that could assist in the repair and restoration of homeostasis, or
prevention of hearing loss?
Intervention in spiral ligament degeneration could take
several forms: (i) stimulation of the fibrocytes’ natural
proliferative capacity to increase repair potential; (ii) alteration
of the physiology of the cells to enhance their homeostatic
activities, e.g., through transfection with genes to overexpress
functional proteins, or even to express new proteins that might
support other cells in the cochlea (e.g., growth factors); and (iii)
direct replacement of fibrocytes through cellular transplantation.
These options require a better knowledge of the functions of
fibrocytes and ways to manipulate them, as well as a source of
fibrocytes in vitro. The latter provides not only an experimental
platform in which to study them (see for example Qu et al., 2006)
but also a possible source of cells for transplantation therapy.
Accordingly, stem cells that have the potential to form
fibrocytes, or direct culture of cochlear fibrocytes are possible
ways forward in achieving the options suggested above. The
developmental germ layer of origin of fibrocytes is mesoderm,
and as cochlear fibrocytes form part of a connective tissue,
they are thus considered to be mesenchymal cells. Such cells
commonly retain a proliferative capacity throughout life and
can thus be stimulated to grow; a related cell type, circulating
fibrocytes in blood, are involved in wound healing and scar
formation, producing myofibroblasts in fibrotic lesions (Quan
et al., 2006). However, although a small degree of proliferation
has been detected within the lateral wall in adult cochlea (Li
et al., 2017), this proliferative capacity seems to be insufficient
to maintain fibrocyte populations or reverse the degenerative
processes. One positive outcome though of this proliferative
capacity is that once removed from the lateral wall it has proved
FIGURE 5 | Monolayer fibrocyte culture after immunofluorescence labeling
for caldesmon (green) and Na, K, ATPase (red). The cells exhibit a mixed
phenotype with some cells labeled strongly for both, and others labeled
primarily for the Na, K, ATPase. Scale bar = 100 µm. Image taken from
conference presentation, cited in published proceedings by Furness (2014).
possible to grow fibrocytes in vitro (Gratton et al., 1996; Suko
et al., 2000; Figure 5). Alternatively, they could be derived
from mesenchymal stem cells (MSCs) that are repurposed into
fibrocytes (Kamiya et al., 2007).
Fibrocyte monolayer cultures are obtained by extracting
pieces of spiral ligament and placing them in culture wells
with a coverslip over the top (Figure 5). After a few days, the
cells appear in the well around the ligament pieces (Gratton
et al., 1996) and these can then be passaged into sub-cultures.
Characterization of these cultures at first suggested that they
contained type I fibrocytes as they were negative for Na,
K, ATPase but positive for other markers suggested being
characteristic of type I cells (Gratton et al., 1996; Suko et al.,
2000). However, such classification is difficult to verify as it relies
on visual confirmation and is not quantitative. For example,
semi-quantitative analysis has shown that type I fibrocytes do
express moderate levels of Na, K, ATase relative to type III
and type IV fibrocytes which express none, whilst type II and
type V express the most (Mahendrasingam et al., 2011b). Other
substrates are also possible, and 3D culturing of fibrocytes is
another way forward. Preliminary work in our lab (Furness,
2014) has shown that fibrocytes can be grown on a variety of
substrates and 3D culturing of type III fibrocytes from guinea
pig in hydrogels has been successful (Kelly et al., 2012). This
paves the way for novel strategies to grow fibrocytes and use of
an appropriate matrix that could direct the phenotypes of the
cultured cells, even to potentially ‘‘bioprinting’’ a replacement
ligament in vitro.
The use of MSCs as an alternative to cultured fibrocytes
also has some evidence to support it. It has been shown in one
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mouse model where the cochlear lateral wall was damaged by a
mitochondrial toxin, that transplantation of MSCs by injection
into the semi-circular canal located near to the cochlea produced
some recovery of hearing function after loss (Kamiya et al.,
2007). In this study, the MSCs were postulated to become
fibrocytes once they had been integrated into the lateral wall
and other regions containing fibrocytes (e.g., the spiral limbus
running along the organ of Corti—Figure 1). Although there
was no ultrastructural evidence that these transplantedMSCs had
become fibrocytes, nevertheless they were in the correct locations
and expressed connexin 26 and 30 as found in native fibrocytes.
Whilst the mitochondrial toxin approach used in their study
is not a natural degenerative process, nevertheless a hallmark
of the degeneration we have observed is mitochondrial damage
(Mahendrasingam et al., 2011b), hence giving confidence to the
notion that a cell-replacement therapy for fibrocytes is a practical
way forward.
Genetic engineering of fibrocytes is a relatively novel
concept and there are a lot of unknowns as it is a strategy
that has not been explored to any great extent. Cultures of
fibrocytes can be used to test transfection strategies and develop
either genetically engineered fibrocytes for transplantation or
transfection methods that could be applied to native cells in vivo.
For example, using cultured fibrocytes, we can test whether
transfection will enable them to generate survival factors and
release them. If genetically engineered cells are successfully
incorporated into the lateral wall, they could be used to enhance
the survival of other cell types in the cochlea (see below).
Fibrocytes have been targeted in a very limited number of studies
for transfection (only two to our knowledge: Zhuo et al., 2008;
Oh et al., 2012).
Finally, it may also be possible to functionalize the fibrocytes
in novel ways, e.g., by optogenetics to enable them to be more
effective in potassium transport. A recently developed light-
sensitive potassium channel shows that it may be possible to alter
their potassium transport ability in response to light (Alberio
et al., 2018). This could potentially be used to manipulate EP
generation by stimulating fibrocytes through an external route
in vivo. These approaches are clearly speculative, but there is
much to be gained from exploring these potential new avenues.
OTHER ADVANTAGES OF FIBROCYTE
MANIPULATION
Arresting the degeneration of the lateral wall is likely to have
other consequences for hearing function if the degeneration
of hair cells and/or the spiral ganglion in SNHL is, to some
extent, triggered by fibrocyte degeneration (Mahendrasingam
et al., 2011b). Thus, lateral wall repair could potentially
prevent subsequent SNHL. Furthermore, engineering fibrocytes
to express certain growth factors could increase the longevity
of the replacement fibrocytes and also be used to support
long-term survival of both hair cells and supporting cells in
the organ of Corti. Insulin-like growth factor 1 (IGF1) is
thought to be a survival factor for hair cells and is currently
undergoing clinical trials as a therapeutic agent (Yamamoto
et al., 2014; Yamahara et al., 2015). Another growth factor
that is potentially useful is brain-derived neurotrophic factor
(BDNF) which helps to support SGNs (Leake et al., 2011).
Survival of the SGNs is a requirement for the successful
use of a cochlear implant long term after profound hearing
loss caused by hair cell loss. This prosthetic device produces
electrical pulses that stimulate SGNs and provides a signal
that preserves some of the frequency content of the stimulus,
replacing that derived from the missing hair cells, which
normally are innervated by the neurons. The implant is
amenable to working together with biological regenerative
therapies (Roemer et al., 2017).
CONCLUSIONS
The fibrocytes of the lateral wall of the cochlea are known to go
missing in certain forms of hearing loss, and temporally, show
early signs of loss of degeneration in humans and animal models.
This leads to potential breakdown of cochlear homeostatic
mechanisms and loss of the endocochlear potential. An under-
recognized category of hearing loss—MHL—seems to be the
likely consequence of this degeneration, and it may lead to
SNHL in later stages. Fibrocytes thus constitute a relatively novel
target in strategies to prevent hearing loss. Another positive
attribute of these cells is that they are especially amenable to both
investigation in vitro and enhancement or replacement in vivo
because of their proliferative capacity which enables them to
be grown in culture from adult cochleae. Therapeutic strategies
involving fibrocytes thus hold great potential for the future.
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